- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT01056224
Effect of Remifentanil Boluses on Hemodynamics in Skull Pin Insertion
The Dose Effects of Remifentanil Boluses on the Hemodynamic Response to Skull Pin Insertion.
연구 개요
상세 설명
Skull pin insertion is commonly required for craniotomies and cervical spine surgery. It is a brief but highly stimulating maneuver performed following induction, during a period of light anesthesia, and may cause significant rise in blood pressure, heart rate and intracranial pressure if not anticipated and treated.
A wide variety of methods have been shown to be effective at blunting this hypertensive response. These include intravenous agents such as fentanyl, sufentanil, clonidine, ketamine and magnesium sulphate, local anesthetic methods such as injection at pin sites or full scalp blocks, deepening the volatile agent, oral premedication or a combination of these methods. There is no consensus on which of these methods is the best. Many anesthesiologists simply use boluses of propofol - a reliable way of accomplishing this effect with a familiar drug. It is also very common for anesthesiologists to use remifentanil, by increasing the infusion rate and or bolusing.
Remifentanil is an ultra-short acting opiate with such rapid onset and offset, that it is most easily and safely delivered by infusion. Increasingly in the literature, however, are reports of remifentanil administered as boluses rather than infusions. Boluses may be ideal for very short stimulating procedures such as intubation and skull pin fixation where a quick onset and offset are desired. Although the safety of bolusing remifentanil has been established in many studies , some authors are still apprehensive . Care must be taken to avoid bolusing with greater doses than required since this may lead to bradycardia and hypotension. In non-ventilated patients, respiratory depression is common and chest wall rigidity may occur at doses larger than 4ug/kg9.
Different bolus dose-effect studies have recommended the following for remifentanil in a variety of clinical settings:
- 3-5ug/kg with propofol 2mg/kg for intubation without muscle relaxants ,
- 2ug/kg with propofol TCI (>4ug/ml) and cisatracurium for intubation (no additional hemodynamic benefit using 4ug/kg)
- 1-1.25ug/kg for rapid sequence intubation with thiopentone 5-7mg/kg and succinylcholine 1mg/kg
- ED50 of 1.7ug/kg and ED95 of 2.88ug/kg for good to excellent intubating conditions in both infants and children (when used with 10ug/kg glycopyrrolate and 4mg/kg propofol)
- 3ug/kg (plus 4mg/kg propofol) provides similar intubating conditions when used in place of succinylcholine 2mg/kg for intubation in infants8
Remifentanil is not currently recommended for the following settings:
- As a sole agent for loss of consciousness with a high ED50 of 12ug/kg, lack of reliability and muscle rigidity common at such high doses
- Wide interindividual variability limit its use for labor analgesia (0.2-0.8ug/kg, median dose of 0.4ug/kg)
In neurosurgery, it is common to administer remifentanil as an infusion. Optimal infusion rates have already been investigated for intracranial surgery . However it is increasingly common to administer remifentanil as a bolus particularly during skull pin fixation, due to the desirable quick onset and offset, and there are no studies at present that have investigated optimal dose requirements for boluses in this setting.
At our institution we commonly administer remifentanil as a bolus during skull pin fixation and are interested in determining which bolus doses are safe and effective
연구 유형
등록 (실제)
단계
- 해당 없음
연락처 및 위치
연구 장소
-
-
Ontario
-
Toronto, Ontario, 캐나다, M5T 2S8
- Toronto Western Hospital
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
Patients requiring skull pin fixation and general anesthesia for:
- Elective cervical spine surgery
- Elective craniotomies/brain tumor resection
- Elective transsphenoidal pituitary hypophysectomies
Exclusion Criteria:
Patients with evidence of raised intracranial pressure:
- GSC < 15
- Radiological evidence of significant rise in ICP (e.g. midline shift)
- Vascular anomalies in the brain
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 네 배로
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: 1.25 ug/kg normo-tensive 20-40 year olds
A single bolus dose of 1.25 micrograms per kilogram body weight will be administered at the time of skull pin insertion in normo-tensive patients aged 20 to 40 years old.
|
A single bolus dose of Remifentanil will be administered at the time of skull pin insertion
|
|
실험적: 1.5 ug/kg normo-tensive 20-40 year olds
A single bolus dose of 1.5 micrograms per kilogram body weight will be administered at the time of skull pin insertion in normo-tensive patients aged 20 to 40 years old.
|
A single bolus dose of Remifentanil will be administered at the time of skull pin insertion
|
|
실험적: 1.75 ug/kg normo-tensive 20-40 year olds
A single bolus dose of 1.75 micrograms per kilogram body weight will be administered at the time of skull pin insertion in normo-tensive patients aged 20 to 40 years old.
|
A single bolus dose of Remifentanil will be administered at the time of skull pin insertion
|
|
실험적: 1 ug/kg normo-tensive 65-75 year olds
A single bolus dose of 1 microgram per kilogram body weight will be administered at the time of skull pin insertion in normo-tensive patients aged 65 to 75 years old.
|
A single bolus dose of Remifentanil will be administered at the time of skull pin insertion
|
|
실험적: 1.25 ug/kg normo-tensive 65-75 year olds
A single bolus dose of 1.25 micrograms per kilogram body weight will be administered at the time of skull pin insertion in normo-tensive patients aged 65 to 75 years old.
|
A single bolus dose of Remifentanil will be administered at the time of skull pin insertion
|
|
실험적: 1.5 ug/kg normo-tensive 65-75 year olds
1.5 ug/kg normo-tensive 65-75 year olds A single bolus dose of 1.5 micrograms per kilogram body weight will be administered at the time of skull pin insertion in normo-tensive patients aged 65 to 75 years old. |
A single bolus dose of Remifentanil will be administered at the time of skull pin insertion
|
|
실험적: 1 ug/kg hyper-tensive 65-75 year olds
A single bolus dose of 1 microgram per kilogram body weight will be administered at the time of skull pin insertion in hyper-tensive patients aged 65 to 75 years old.
|
A single bolus dose of Remifentanil will be administered at the time of skull pin insertion
|
|
실험적: 1.25 ug/kg hyper-tensive 65-75 year olds
A single bolus dose of 1.25 micrograms per kilogram body weight will be administered at the time of skull pin insertion in hyper-tensive patients aged 65 to 75 years old.
|
A single bolus dose of Remifentanil will be administered at the time of skull pin insertion
|
|
실험적: 1.5 ug/kg hyper-tensive 65-75 year olds
A single bolus dose of 1.5 micrograms per kilogram body weight will be administered at the time of skull pin insertion in hyper-tensive patients aged 65 to 75 years old.
|
A single bolus dose of Remifentanil will be administered at the time of skull pin insertion
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
기간 |
|---|---|
|
To validate the safety and effectiveness of using remifentanil as a bolus for skull pin fixation
기간: 10 minutes
|
10 minutes
|
2차 결과 측정
결과 측정 |
기간 |
|---|---|
|
To determine the optimal doses for remifentanil in order to blunt the hemodynamic changes associated with skull pin fixation
기간: 10 minutes
|
10 minutes
|
|
to assess variability in dose requirements of remifentanil
기간: 10 minutes
|
10 minutes
|
|
to compare the dose effects in younger (20-40yo) vs. older (65-75yo) age groups
기간: 10 minutes
|
10 minutes
|
|
to compare the dose effects in older (65-75yo) age groups in hypertensive versus non-hypertensive patients
기간: 10 minutes
|
10 minutes
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Atul Prabhu, MD, University Health Network, Toronto
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- 05-0684-B
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .